Sign up Australia
Proactive Investors - Run By Investors For Investors

CannPal Animal Therapeutics leveraged to 'lucrative potential' of growing market

CannPal Animal Therapeutics Ltd (ASX:CP1) founder and managing director Layton Mills speaks to Proactive Investors about the innovative pet pharmaceutical company, which operates in the medical cannabis space.

"The goal for the company is really to develop products that can address clear, unmet needs in the animal health market, focusing on companion animals. We have a lead drug candidate that's currently in development, that's CPAT-01, which we're developing as a pain control in dogs... we've just finished wrapping up our first Phase 1A Pharmacokinetic and Safety Study, which is a really exciting milestone for the company," says Mills.

CannPal Animal Therapeutics is simultaneously developing nutraceutical products using Cannabidiol, a less regulated cannabinoid than THC and CBD, in order to generate early revenues as the core pharmaceutical products go through the necessary approvals processes.

Join our Crypto, Blockchain and Cannabis Telegram group here  
Meet High Peak Royalties Ltd, Yandal Resources, MMJ PhytoTech Ltd, Minotaur Exploration Ltd and Hydroponics Company Ltd at our event, Sydney , 22 October 2018. Register here »
View full CP1 profile View Profile

CannPal Animal Therapeutics Ltd Timeline

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use